Page 16 - Cv Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Equities Research Analysts’ updated eps estimates for Tuesday, May 24th: Central Garden & Pet (NASDAQ:CENTA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $45.00 price target on the stock. According to Zacks, “Central Garden & Pet Company is a leading innovator, marketer […]

CV Sciences (OTCMKTS:CVSI – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment […]

CV Sciences (OTCMKTS:CVSI – Get Rating) released its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02), MarketWatch Earnings reports. CV Sciences had a negative net margin of 77.58% and a negative return on equity of 169.87%. Shares of CVSI traded down $0.00 […]

CV Sciences, Inc. (OTCQB:CVSI) Q1 2022 Results Conference Call May 16, 2022 10:00 AM ET Company Participants Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Scott...

NEW YORK, April 11, 2022 /PRNewswire/ --UNITED STATES DISTRICT COURTDISTRICT OF NEVADAIn re: CV SCIENCES, INC. SECURITIES LITIGATIONCase No. 2:18-...